PRECIOUS the group
PRECIOUS the group
PRECIOUS the group

University of Nottingham

Logo University of Nottingham

Prof. Philip Bath


Principal Investigator

Leader WP 2


Phone: +44 115 823 1765




undefinedGoogle Scholar


University of Nottingham


University Park

NG7 2RD Nottingham

United Kingdom



PRECIOUS Team University of Nottingham

Polly Scutt 

Polly Scutt

PhD Student







Institute presentation

The University is a World top 75 University (top 1% in world, top 30 in Europe, top 10 in UK, top in UK for businesses’ finding graduate recruits, world’s greenest University) with 43,000 students (including students at the Malaysian and China campuses). In the UK 2014 Research Excellence Framework, the University ranked 8th for research power; >80% of staff were ranked “world-leading’ or ‘internationally excellent’. The Faculty of Medicine and Health Sciences hosts schools of Medicine, Nursing, and Veterinary Medicine. The Division of Clinical Neuroscience (Head: Bath) is the largest Division in the University, and stroke constitutes the largest group within neuroscience. The Faculty hosts the UK-registered Nottingham Clinical Trials Services Unit, two NIHR Biomedical Research Units, and Cochrane Collaborative groups. 


The Stroke Research Group has four principal investigators leading translational research encompassing preclinical models of stroke, phase I and II trials, phase III safety/efficacy trials, and late stage translation of research into practice. The Stroke Trials Unit hosts 6 PhD students, and is currently coordinating four trials: 


  • Medical Research Council-funded ENOS: acute stroke, 4,011 participants from 173 sites in 21 countries/5 continents - trial completed, primary publication in Lancet 2015; CI: Bath. This trial tested the repurposing of transdermal glyceryl trinitrate (GTN), a treatment for angina, as a potential treatment for acute stroke.
  • British Heart Foundation-funded RIGHT-2: ultra-acute stroke, currently 7 of 850 participants from 6 of 30 sites in UK - recruiting; CI Bath. The trial is testing GTN in patients with ultra-acute stroke since this subgroup benefitted in ENOS and in an earlier pilot trial, RIGHT. 
  • Health Technology Assessment-funded TARDIS: acute ischaemic stroke ot TIA, currently 2935 of 4100 participants from 106 sites in 4 countries/2 continents; CI: Bath. This trial is testing intensive versus guideline antiplatelet therapy in patients with acute stroke or transient ischemic attack.
  • Health Technology Assessment-funded TICH-2: acute haemorrhagic stroke, currently 1272 of 2000 participants from 85 sites in 3 countries; CI: Sprigg. This trial is testing the repurposing of tranexamic acid, a treatment for surgical bleeding, as a potential treatment for acute intracerebral haemorrhage.

These trials include older patients, and use bespoke software for data collection, SAE and imaging adjudication. The trial interventions are readily available for use if the trial is positive.


Main tasks attributed in the project:


UNOTT will be leading undefinedWP7 Statistical Analysis.


Newsletter Subscription

Social Media


Contact us

Contact us